Supporting axis — cortisol, thyroid, and circadian glucose

You can run the cleanest G-L-P 1 protocol on the planet, dial in Metformin, layer in 5-Amino-1MQ, and still wake up at six A-M with a fasting glucose of one hundred fifteen. Not because the protocol failed. Because three upstream systems — cortisol, thyroid, and the circadian clock — are dumping glucose into your bloodstream before your first meal touches the table. Phase 1 and Phase 2 of this Path were the cellular-level interventions. This chapter is the AXIS LAYER. Skip it and you'll plateau at "better but not fixed." [short pause] What's actually happening at four A-M. The CORTISOL AWAKENING RESPONSE is not a bug — it's the physiological alarm clock. Practitioner consensus describes the pattern clearly: cortisol should peak in the early morning — the C-A-R — decline through the day, and bottom out near midnight. That morning spike mobilizes glucose for the day's demands. In a regulated system, it's elegant. In a dysregulated one, it's the reason your C-G-M trace shows a smooth upward drift from three A-M to seven A-M with no food on board. Here's the mechanism. Cortisol opposes insulin at the liver. When the H-P-A axis fires the C-A-R, hepatic gluconeogenesis ramps — the liver dumps glucose into circulation to prepare you for movement. In a healthy substrate, the pancreas responds in lockstep, insulin sensitivity is intact, and the glucose gets cleared. In an H-P-A-dysregulated substrate, the cortisol spike is either too high, too prolonged, or arriving on top of nighttime cortisol that never fully cleared. The result: the DAWN PHENOMENON. Fasting glucose one hundred five to one hundred thirty with no carbohydrate input. The practitioner corpus is explicit on the rollercoaster pattern — high morning cortisol, an afternoon dip that feels like anxiety or sudden hunger, an evening rebound that wrecks sleep. That afternoon dip is when most blood sugar protocols quietly fail. The user assumes it's hypoglycemia and reaches for carbs. It's adrenal, not glycemic. [short pause] The thyroid lever nobody pulls. T-3 metabolism and glucose metabolism are not parallel systems — they're the same system. The corpus surfaces a mechanism most blood sugar protocols miss entirely: a significant fraction of circulating T-3 is allocated specifically to glucose metabolism. When glucose throughput drops — ketogenic interventions, prolonged caloric restriction, G-L-P 1-induced hypophagia — measured T-3 levels fall. Not because the thyroid is failing, but because the demand for glucose-allocated T-3 dropped. The thyroid down-regulates appropriately. This matters for the Phase 2 patient running Tirzepatide or Semaglutide. Six weeks in, free T-3 is low-normal, T-S-H is creeping up, and the patient is convinced the G-L-P 1 broke their thyroid. It didn't. The substrate is unambiguous on the cascade: chronically elevated cortisol drives the conversion of T-4 to REVERSE T-3 instead of active T-3, blocking T-3 receptor sites at the cellular level. The peripheral tissue reads "low energy state" and metabolism slows. Fat loss stalls. Morning glucose rises. The body increases reverse T-3 production specifically to block T-3 effects when nutrients are scarce — or when the brain perceives scarcity. A G-L-P 1 that crushes appetite plus a stress-elevated cortisol baseline reads as famine. The thyroid axis responds accordingly. Pulling reverse T-3 and free T-3 — not just T-S-H — is non-negotiable in this Path. [short pause] Circadian glucose — the meal-timing lever. The corpus is consistent: insulin sensitivity is highest in the morning and declines through the day. But the more interesting practitioner observation is the inverted one — evening carbohydrates, paradoxically, can produce better overnight glycemic control than morning carbohydrates for some patients. The mechanism is that evening insulin preferentially shuttles glucose into muscle — post-resistance-training windows especially — rather than into adipocytes, and the resulting serotonin bump supports melatonin synthesis and SLEEP DEPTH. Sleep depth then loops back. Four nights of restricted sleep — four and a half hours — drops insulin sensitivity twenty-five to thirty percent and elevates cortisol. One week of partial sleep restriction can move a metabolically healthy adult into pre-diabetic-range glucose handling. Subjects in the sleep-loss literature took forty percent longer than baseline to clear a glucose challenge. Glucose regulation is downstream of sleep architecture, not the other way around. This is why the Phase 3 supporting axis stack uses peptides that target sleep depth and circadian regulation directly — not as "nice-to-have" additions but as primary glucose-regulation tools. [short pause] Here is the Phase 3 supporting axis stack, weeks five through ten, layered on top of Phase 1 and Phase 2. Five compounds. First, DSIP. One hundred to three hundred micrograms, subcutaneous, nightly, thirty to sixty minutes before bed. Expert-tier evidence. It restores DELTA-WAVE sleep architecture. Non-habit-forming, does not suppress REM. Effects begin night one to three; deeper sleep is measurable by week two. Next, Epithalon. Five hundred micrograms to one milligram, subcutaneous, nightly, in ten to twenty day cycles, two to three times per year. Experimental tier. It supports pineal restoration and endogenous melatonin recovery. Practitioner consensus is firm: cycle it, do not run continuously. Third, Selank. Two hundred fifty to five hundred micrograms, intranasal, one to two times daily, morning and early afternoon. Expert tier. It targets the H-P-A axis stress response and reduces the sleep-disrupting anxiety load. Pairs with DSIP — does not replace it. Fourth, Tesamorelin. One to two milligrams, subcutaneous, five times per week, in the evening, four to six hours post-meal. Expert tier. G-H pulse restoration improves overnight glucose disposal and visceral fat reduction. Pull fasting glucose at week four — a minor transient rise is expected. And fifth, Berberine. Five hundred milligrams, oral, two to three times daily with meals. Clinical tier. A-M-P-K activation; addresses dawn-phenomenon hepatic gluconeogenesis. Stack with Phase 1 Metformin only at a reduced Metformin dose. If a thyroid panel at week four shows free T-3 below three point zero picograms per milliliter with reverse T-3 above twenty nanograms per deciliter: the practitioner corpus is thin on direct peptide intervention for reverse-T-3 dominance — track and report. Adrenal support and circadian repair are the upstream levers; thyroid-direct dosing is a physician decision, not a peptide-stack decision. [short pause] What you should feel. Weeks five and six: sleep depth measurably improves. Resting heart rate drops three to seven beats per minute overnight; the C-G-M overnight trace flattens. Morning fasting glucose drops five to fifteen milligrams per deciliter. The afternoon dip attenuates. Weeks seven and eight: the cortisol awakening response normalizes — you wake without the jolt-and-grind sensation. Free T-3 begins rising as reverse T-3 falls. Energy stabilizes through the afternoon without a carbohydrate rescue. Weeks nine and ten: visceral fat — waist circumference, not scale weight — drops measurably. Overnight glucose smooths into a flat low line. Dawn phenomenon resolves or attenuates to under ten milligrams per deciliter of drift. [short pause] What's NOT happening yet. DSIP is not a sedative. If you're expecting Ambien-grade unconsciousness, you'll think it failed. It restores architecture, not sedation depth. The signal is morning H-R-V and C-G-M flatness, not "I felt knocked out." Epithalon does not work continuously. Practitioner consensus is explicit: run it in ten to twenty day cycles, then off. Continuous dosing burns the receptor sensitivity that makes it work in the first place. The thyroid panel will not normalize in two weeks. Reverse-T-3 dominance unwinds on a six to twelve week timeline once cortisol stabilizes. Pulling labs at week six and panicking that nothing changed is the most common Phase 3 mistake. Cortisol does not respond to peptides alone. The corpus is clear: sleep, sunlight in the first hour after waking, and meal timing are upstream of any compound intervention. Selank reduces the anxiety overlay; it does not replace circadian discipline. Tesamorelin will transiently raise fasting glucose in weeks one and two of the layer. This is expected G-H-axis behavior. Pull labs at week four, not week two, before adjusting dose. The corpus describes this axis. Pull the morning cortisol, the reverse T-3, and the overnight C-G-M trace — those three datasets tell you whether the upstream lever is moving before the downstream numbers shift.